SCHEMBL1749211

SCHEMBL1749211

COc1cc2c(-c3cc4c(CNCc5ccccc5)ccnc4n3S(=O)(=O)c3ccc(C)cc3)cn(C)c2cc1OC

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.39
PCSK9 Q8NBP7 2/20 0.37
NOD2 Q9HC29 1/20 0.35
NOD1 Q9Y239 1/20 0.35
PTGDR2 Q9Y5Y4 4/20 0.35
TP53 P04637 2/20 0.34
HTR6 P50406 2/20 0.34
BRD4 O60885 1/20 0.34
ALDH1A1 P00352 1/20 0.34
F2 P00734 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TRIM24 O15164 1/20 0.34
TRIM33 Q9UPN9 1/20 0.34
EED O75530 1/20 0.34
SCN9A Q15858 1/20 0.33
BCHE P06276 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1748721 0.93 IGF1R (0.37) IGF1RPCSK9PTGDR2HTR6TRIM24
SCHEMBL1749187 0.92 BCHE (0.36) IGF1RPCSK9PTGDR2HTR6TRIM24
SCHEMBL1748804 0.90 IGF1R (0.39) IGF1RPCSK9PTGDR2TP53HTR6
SCHEMBL1749195 0.89 IGF1R (0.33) IGF1RPCSK9TP53ALDH1A1EED
SCHEMBL1749227 0.89 APLNR (0.38) IGF1RPTGDR2TP53HTR6ALDH1A1
SCHEMBL1748968 0.88 IGF1R (0.37) IGF1RPCSK9PTGDR2TP53HTR6
SCHEMBL1749143 0.88 IGF1R (0.37) IGF1RPCSK9TP53HTR6ALDH1A1
SCHEMBL1749798 0.85 PTGDR2 (0.39) IGF1RPCSK9PTGDR2TP53HTR6
SCHEMBL1748824 0.85 IGF1R (0.39) IGF1RPCSK9PTGDR2TP53HTR6
SCHEMBL1749257 0.85 IGF1R (0.39) IGF1RPCSK9PTGDR2TP53HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US disclosed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885PCSK9 3328/4885NOD2 2950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.